Prognostic Factors in Adult Patients up to 60 Years Old With Acute Myeloid Leukemia and Translocations of Chromosome Band 11q23: Individual Patient Data-Based Meta-Analysis of the German Acute Myeloid Leukemia Intergroup

被引:71
作者
Krauter, Juergen
Wagner, Katharina
Schaefer, Irina
Marschalek, Rolf
Meyer, Claus
Heil, Gerhard
Schaich, Markus
Ehninger, Gerhard
Niederwieser, Dietger
Krahl, Rainer
Buechner, Thomas
Sauerland, Cristina
Schlegelberger, Brigitte
Doehner, Konstanze
Doehner, Hartmut
Schlenk, Richard F.
Ganser, Arnold
机构
[1] Hannover Med Sch, Dept Hematol, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Hemostasis, D-30625 Hannover, Germany
[3] Hannover Med Sch, Dept Oncol, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Stem Cell Transplantat, D-30625 Hannover, Germany
[5] Hannover Med Sch, Dept Cellular & Mol Pathol, D-30625 Hannover, Germany
[6] Goethe Univ Frankfurt, Bioctr, Zentrum Arzneimittelforsch Entwicklung & Sicherhe, Diagnost Ctr Acute Leukemia,Inst Pharmaceut Biol, Frankfurt, Germany
[7] Univ Klinikum CG Carus, Med Klin & Poliklin 1, Dresden, Germany
[8] Univ Leipzig, Dept Hematol & Oncol, Leipzig, Germany
[9] Univ Klinikum Munster, Med Klin & Poliklin A, Munster, Germany
[10] Univ Munster, Dept Med Informat & Biomath, Munster, Germany
[11] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
关键词
STEM-CELL TRANSPLANTATION; HIGH-DOSE CYTARABINE; DE-NOVO; POSTREMISSION THERAPY; PROLONGED MAINTENANCE; MLL GENE; AML; INDUCTION; SURVIVAL; CANCER;
D O I
10.1200/JCO.2008.16.7981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To identify risk factors for induction success and overall survival (OS) and relapse-free survival (RFS) and to evaluate the impact of allogeneic stem-cell transplantation (alloSCT) in adult patients up to 60 years old with acute myeloid leukemia (AML) and reciprocal translocations involving chromosome band 11q23 [t(11q23)]. Patients and Methods An individual patient data-based meta-analysis was performed on 180 adult patients with AML and t(11q23). These patients were identified by cytogenetics and/or molecular techniques and treated within eight prospective multicenter trials of the German AML Intergroup. The median follow-up time was 53 months. Results Complete remission rate was 71%. Favorable factors for induction success were the presence of a t(9; 11), t(11q23) as a sole aberration, and de novo leukemia. OS rate at 4 years was 29%. Translocations other than t(9; 11), platelets less than the median, secondary leukemia, and peripheral blasts greater than the median were adverse risk factors for OS. RFS rate at 4 years was 29%. The presence of a t(6; 11) and peripheral blasts greater than the median had a negative impact on RFS. Three risk groups for OS and RFS could be defined by the combination of these factors with 4-year OS rates of 50%, 28%, and 5% and 4-year RFS rates of 37%, 26%, and 5%. An alloSCT from matched related or unrelated donors in first complete remission was beneficial, especially in t(6; 11)-negative patients. Conclusion Risk stratification of AML patients with reciprocal translocations of chromosome band 11q23 is feasible based on the translocation partner and clinical parameters. J Clin Oncol 27: 3000-3006. (C) 2009 by American Society of Clinical Oncology
引用
收藏
页码:3000 / 3006
页数:7
相关论文
共 37 条
[1]   COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY [J].
ANDERSEN, PK ;
GILL, RD .
ANNALS OF STATISTICS, 1982, 10 (04) :1100-1120
[2]   Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly:: confirmation of the existence of different entities with 11q23 breakpoint [J].
Archimbaud, E ;
Charrin, C ;
Magaud, JP ;
Campos, L ;
Thomas, X ;
Fière, D ;
Rimokh, R .
LEUKEMIA, 1998, 12 (01) :25-33
[3]   11q23 balanced chromosome aberrations in treatment- related myelodysplastic syndromes and acute leukemia:: Report from an international workshop [J].
Bloomfield, CD ;
Archer, KJ ;
Mrózek, K ;
Lillington, DM ;
Kaneko, Y ;
Head, DR ;
Dal Cin, P ;
Raimondi, SC .
GENES CHROMOSOMES & CANCER, 2002, 33 (04) :362-378
[4]   Adult de novo acute myeloid leukemia with t(6;11)(q27;q23) -: Results from cancer and leukemia group B study 8461 and review of the literature [J].
Blum, W ;
Mrózek, K ;
Ruppert, AS ;
Carroll, AJ ;
Rao, KW ;
Pettenati, MJ ;
Anastasi, J ;
Larson, RA ;
Bloomfield, CD .
CANCER, 2004, 101 (06) :1420-1427
[5]   Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia [J].
Büchner, T ;
Berdel, WE ;
Schoch, C ;
Haferlach, T ;
Serve, HL ;
Kienast, J ;
Schnittger, S ;
Kern, W ;
Tchinda, J ;
Reichle, A ;
Lengfelder, E ;
Staib, P ;
Ludwig, WD ;
Aul, C ;
Eimermacher, H ;
Balleisen, L ;
Sauerland, MC ;
Heinecke, A ;
Wöermann, B ;
Hiddemann, W .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2480-2489
[6]   6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group [J].
Büchner, T ;
Hiddemann, W ;
Berdel, WE ;
Wörmann, B ;
Schoch, C ;
Fonatsch, C ;
Löffler, H ;
Haferlach, T ;
Ludwig, WD ;
Maschmeyer, G ;
Staib, P ;
Aul, C ;
Grüneisen, A ;
Lengfelder, E ;
Frickhofen, N ;
Kern, W ;
Serve, HL ;
Mesters, RM ;
Sauerland, MC ;
Heinecke, A .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4496-4504
[7]   Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome:: results of a phase I-II study [J].
Bunjes, D ;
Buchmann, I ;
Duncker, C ;
Seitz, U ;
Kotzerke, J ;
Wiesneth, M ;
Dohr, D ;
Stefanic, M ;
Buck, A ;
Harsdorf, SV ;
Glatting, G ;
Grimminger, W ;
Karakas, T ;
Munzert, G ;
Döhner, H ;
Bergmann, L ;
Reske, SN .
BLOOD, 2001, 98 (03) :565-572
[8]   Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].
Byrd, JC ;
Mrózek, K ;
Dodge, RK ;
Carroll, AJ ;
Edwards, CG ;
Arthur, DC ;
Pettenati, MJ ;
Patil, SR ;
Rao, KW ;
Watson, MS ;
Koduru, PRK ;
Moore, JO ;
Stone, RM ;
Mayer, RJ ;
Feldman, EJ ;
Davey, FR ;
Schiffer, CA ;
Larson, RA ;
Bloomfield, CD .
BLOOD, 2002, 100 (13) :4325-4336
[9]   Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].
Cheson, BD ;
Bennett, JM ;
Kopecky, KJ ;
Büchner, T ;
Willman, CL ;
Estey, EH ;
Schiffer, CA ;
Döhner, H ;
Tallman, MS ;
Lister, TA ;
LoCocco, F ;
Willemze, R ;
Biondi, A ;
Hiddemann, W ;
Larson, RA ;
Löwenberg, B ;
Sanz, MA ;
Head, DR ;
Ohno, R ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649
[10]   An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes [J].
Corral, J ;
Lavenir, I ;
Impey, H ;
Warren, AJ ;
Forster, A ;
Larson, TA ;
Bell, S ;
McKenzie, ANJ ;
King, G ;
Rabbitts, TH .
CELL, 1996, 85 (06) :853-861